NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women

Pharmacogenetics

Volumn 13, Issue 7, 2003, Pages 399-407

  Van Der Hel, Olga L ^a,c   Peeters, Petra H M ^a   Hein, David W ^b   Doll, Mark A ^b   Grobbee, Diederick E ^a   Kromhout, Daan ^c   Bueno De Mesquita, H Bas ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b University of Louisville School of Medicine   (United States)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Breast cancer; Glutathione S transferase; N acetyltransferase; Nested case control; Smoking

Indexed keywords

ACYLTRANSFERASE; GLUTATHIONE TRANSFERASE;

ACETYLATION; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CATALYSIS; CIGARETTE SMOKING; DETOXIFICATION; DNA ADDUCT; ENVIRONMENTAL FACTOR; FEMALE; GENE; GENE ACTIVATION; GENE DELETION; GENE INACTIVATION; GENETIC POLYMORPHISM; GSTM1 GENE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ACETYLTRANSFERASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENE DOSAGE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MIDDLE AGED; NETHERLANDS; ODDS RATIO; POLYMORPHISM, GENETIC; POSTMENOPAUSE; REGISTRIES; RISK FACTORS; SMOKING; TIME FACTORS;

EID: 0042868370     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200307000-00005     Document Type: Article

References (39)

1. www-dep.iarc.fr/eucan/eucan.htm. Berrino F, Capocaccia R, Estève J, Gatta G, Micheli A, Hakulinen T, Sant M, Verdecchia A. Survival of Cancer patients in Europe: The EUROCARE-2 Study. IARC Scientific Publications No 151. Lyon, International Agency for Research on Cancer, 1999.
2. Khuder SA, Mutgi AB, Nugent S. Smoking and breast cancer: a meta-analysis. Rev Environ Health 2001; 16:253-261.
3. Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease. Br J Cancer 2002; 87:1234-1245.
4. Delfino RJ, Smith C, West JG, Lin HJ, White E, Liao SY, et al. Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotype. Pharmacogenetics 2000; 10:461-469.
5. Perera FP, Estabrook A, Hewer A, Channing K, Rundle A, Mooney LA, et al. Carcinogen-DNA adducts in human breast tissue. Cancer Epidemiol Biomarkers Prev 1995; 4:233-238.
6. Li D, Wang M, Dhingra K, Hittelman WN. Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res 1996; 56:287-293.
7. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8:843-854.
8. Kelsey KT, Hankinson SE, Colditz GA, Springer K, Garcia Closas M, Spiegelman D, et al. Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol Biomarkers Prev 1997; 6:511-515.
9. Garcia-Closas M, Kelsey KT, Hankinsen SE, Spiegelman D, Springer K, Willett WC, et al. Glutathione S-transferase mu and theta polymorphisms and breast cancer susceptibility. J Natl Cancer Inst 1999; 91; 1960-1964.
10. Millikan R, Pittman G, Tse CK, Savitz DA, Newman B, Bell D. Glutathione S-transferases M1, T1, and P1 and breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9:567-573.
11. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cytochrome P4501A1 and glutathione S-transferase genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995; 55:3483-3485.
12. Verschuren WMM, van Leer EM, Blokstra A, Seidell JC, Smit HA, Bueno de Mesquita HB, et al. Cardiovascular disease risk factors in the Netherlands. Neth J Cardiol 1993; 6:205-210.
13. de Winter GA, Coebergh JWW, van Leeuwen FE, Schouten LJ. Incidence of Cancer in the Netherlands 1989: First Report of the Netherlands Cancer Registry. Utrecht: Hoonte-Holland; 1990.
14. Van den Brandt PA, Schouten LJ, Goldbohm RA, Dorant E, Hunen PM. Development of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological Research. Int J Epidemiol 1990; 19: 553-558.
15. Doll MA, Hein DW. Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal Biochem 2001; 288:106-108.
16. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9:29-42.
17. Chen CL, Liu Q, Relling MY. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 1996; 6:187-191.
18. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995; 55:5226-5229.
19. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999; 58:1759-1764.
20. Payton MA, Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants. Biochem Pharmacol 1998; 55:361-366.
21. Butcher NJ, Ilett KF, Minchin RF. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenetics 1998; 8:67-72.
22. Smelt VA, Mardon HJ, Sim E. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2. Pharmacol Toxicol 1998; 83:149-157.
23. Arylamine N-acetyltransferase Nomenclature Committee. http://www.louisville.edu/medschool/pharmacology/NAT.html. Updated 5 February 2003.
24. Hein DW, Doll MA, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 1995; 55:3531-3536.
25. de Waard F, Collette HJ, Rombach JJ, Baanders-van Halewijn EA, Honing C. The DOM project for the early detection of breast cancer, Utrecht, the Netherlands. J Chronic Dis 1984; 37:1-44.
26. Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, et al. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer 2001; 92:220-225.
27. Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia Closas M, Spiegelman D, et al. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis 1997; 18:2127-2132.
28. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, et al. Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol Biomarkers Prev 2001; 10:229-236.
29. Millikan RC. NAT1*10 and NAT1*11 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9:217-219.
30. Zheng W, Deitz AC, Campbell DR, Wen WQ, Cerhan JR, Sellers TA, et al. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8:233-239.
31. Millikan RC, Pittman GS, Newman B, Tse CK, Selmin O, Rockhill B, et al. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7:371-378.
32. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996; 276:1494-1501.
33. Huang CS, Chern HD, Shen CY, Hsu SM, Chang KJ. Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int J Cancer 1999; 82:175-179.
34. Chang-Claude J, Kropp S, Jager B, Bartsch H, Risch A. Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:698-704.
35. Pfau W, Stone EM, Brockstedt U, Carmichael PL, Marquardt H, Phillips DH. DNA adducts in human breast tissue: association with N-acetyltransferase-2 (NAT2) and NAT1 genotypes. Cancer Epidemiol Biomarkers Prev 1998; 7:1019-1025.
36. Morabia A, Bernstein MS, Bouchardy I, Kurtz J, Morris MA. Breast cancer and active and passive smoking: the role of the N-acetyltransferase 2 genotype. Am J Epidemiol 2000; 152:226-232.
37. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14:1633-1638.
38. Deitz AC, Zheng W, Leff MA, Gross M, Wen WQ, Doll MA, et al. N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9:905-910.
39. Hein DW, Rustan TD, Ferguson RJ, Doll MA, Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol 1994; 66:129-133.